| Source: |
| Type: |
| Beta-Amyloid (Aβ): In Alzheimer’s disease, Aβ peptides tend to misfold and aggregate into oligomers and fibrils. |
| 3232- | EGCG, | (−)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer׳s disease model mice by upregulating neprilysin expression |
| - | in-vivo, | AD, | NA |
| 3237- | EGCG, | (-)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer's disease model mice by upregulating neprilysin expression |
| - | in-vivo, | AD, | NA |
| 3591- | EGCG, | Epigallocatechin-3-Gallate Provides Protection Against Alzheimer's Disease-Induced Learning and Memory Impairments in Rats |
| - | in-vivo, | AD, | NA |
| 3593- | EGCG, | Epigallocatechin Gallate (EGCG) |
| - | Review, | AD, | NA |
| 6784- | EGCG, | Dietary (−)-Epigallocatechin Gallate (EGCG): State-of-the-Art Advances in Bioactivities, Bioavailability Enhancement Strategies, and Applications in Nutrition and Health |
| - | Review, | Nor, | NA |
| 6049- | EGCG, | SeNPs, | Epigallocatechin-3-gallate (EGCG)-stabilized selenium nanoparticles coated with Tet-1 peptide to reduce amyloid-β aggregation and cytotoxicity |
| - | Study, | AD, | PC12 |
| 6824- | EMD, | Neuroprotective, Anti-Inflammatory and Antifibrillogenic Offerings by Emodin against Alzheimer’s Dementia: A Systematic Review |
| - | Review, | AD, | NA |
| 6816- | EMD, | Emodin attenuates Alzheimer's disease by activating the protein kinase C signaling pathway |
| - | in-vivo, | AD, | NA |
| 6817- | EMD, | Emodin inhibits aggregation of amyloid-β peptide 1–42 and improves cognitive deficits in Alzheimer's disease transgenic mice |
| - | in-vivo, | AD, | NA |
| 6818- | EMD, | Emodin Rescued Hyperhomocysteinemia-Induced Dementia and Alzheimer's Disease-Like Features in Rats |
| - | in-vivo, | AD, | NA |
| 6821- | EMD, | Emodin derivatives as promising multi-aspect intervention agents for amyloid aggregation: molecular docking/dynamics simulation, bioactivities evaluation, and cytoprotection |
| - | Study, | AD, | NA |
| 6822- | EMD, | Behavioral, Histopathological, and Biochemical Implications of Aloe Emodin in Copper-Aβ-Induced Alzheimer's Disease-like Model Rats |
| - | in-vivo, | AD, | NA |
| 6826- | EMD, | Exploring the therapeutic potential of natural compounds for Alzheimer's disease: Mechanisms of action and pharmacological properties |
| 6828- | EMD, | Neuroprotective effect of emodin against Alzheimer's disease via Nrf2 signaling in U251 cells and APP/PS1 mice |
| - | in-vitro, | AD, | U251 |
| 3830- | EMD, | Traditional Chinese Medicine: Role in Reducing β-Amyloid, Apoptosis, Autophagy, Neuroinflammation, Oxidative Stress, and Mitochondrial Dysfunction of Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 6378- | Eug, | Effects of Eugenol on the Central Nervous System: Its Possible Application to Treatment of Alzheimer's Disease, Depression, and Parkinson's Disease |
| - | Review, | AD, | NA |
| 6377- | Eug, | Pharmacological Properties and Health Benefits of Eugenol: A Comprehensive Review |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 4068- | FA, | Hyperhomocysteinemia in Alzheimer's disease: the hen and the egg? |
| - | in-vivo, | AD, | NA |
| 4070- | FA, | Folic Acid Supplementation Mitigates Alzheimer's Disease by Reducing Inflammation: A Randomized Controlled Trial |
| - | Trial, | AD, | NA |
| 4071- | FA, | Folate and Alzheimer: when time matters |
| - | Review, | AD, | NA |
| 3710- | FA, | Therapeutic Potential of Ferulic Acid in Alzheimer's Disease |
| - | Review, | AD, | NA |
| 3711- | FA, | A review on ferulic acid and analogs based scaffolds for the management of Alzheimer's disease |
| - | Review, | AD, | NA |
| 3712- | FA, | Ferulic Acid: A Hope for Alzheimer’s Disease Therapy from Plants |
| - | Review, | AD, | NA |
| 3713- | FA, | Protective Effect of Ferulic Acid on Acetylcholinesterase and Amyloid Beta Peptide Plaque Formation in Alzheimer’s Disease: An In Vitro Study |
| - | Review, | AD, | NA |
| 3714- | FA, | Recent Advances in the Neuroprotective Properties of Ferulic Acid in Alzheimer's Disease: A Narrative Review |
| - | Review, | AD, | NA |
| 3715- | FA, | CUR, | PS, | The Additive Effects of Low Dose Intake of Ferulic Acid, Phosphatidylserine and Curcumin, Not Alone, Improve Cognitive Function in APPswe/PS1dE9 Transgenic Mice |
| - | in-vivo, | AD, | NA |
| 3717- | FA, | Neuroprotective Properties of Ferulic Acid in Preclinical Models of Alzheimer's Disease: A Systematic Literature Review |
| - | Review, | AD, | NA |
| 3783- | FA, | Design, Synthesis, and Biological Evaluation of Ferulic Acid-Piperazine Derivatives Targeting Pathological Hallmarks of Alzheimer’s Disease |
| - | NA, | AD, | NA |
| 3782- | FA, | Ferulic acid ameliorates bisphenol A (BPA)-induced Alzheimer’s disease-like pathology through Akt-ERK crosstalk pathway in male rats |
| - | in-vivo, | AD, | NA |
| 3779- | FA, | A review on ferulic acid and analogs based scaffolds for the management of Alzheimer’s disease |
| - | Review, | AD, | NA |
| 3778- | FA, | Recent Advances in the Neuroprotective Properties of Ferulic Acid in Alzheimer’s Disease: A Narrative Review |
| - | Review, | AD, | NA |
| 6884- | FA, | Effects of folic acid supplementation on cognitive function and Aβ-related biomarkers in mild cognitive impairment: a randomized controlled trial |
| - | Trial, | AD, | NA |
| 6867- | FA, | Ang, | Effect of Feru-guard 100M on amyloid-beta deposition in individuals with mild cognitive impairment |
| - | Trial, | AD, | NA |
| 6866- | FA, | Ang, | Effects of Ferulic Acid and Angelica archangelica Extract (Feru-guard ®) on Mild Cognitive Impairment: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Prospective Trial |
| - | Trial, | AD, | NA |
| 6954- | FA, | Folic acid as a potential therapeutic agent for Alzheimer's disease: Effects on inflammatory cytokines, amyloid deposition, and neurotransmitter metabolism |
| - | Trial, | AD, | NA |
| 7829- | FA, | MBS, | Neuroprotective Potential of Mung Bean (Vigna radiata L.) Polyphenols in Alzheimer's Disease: A Review |
| - | Review, | AD, | NA |
| 6913- | FIS, | Fisetin inhibits tau aggregation by interacting with the protein and preventing the formation of β-strands |
| - | in-vitro, | AD, | NA |
| 6917- | FIS, | Dietary flavonoid fisetin regulates aluminium chloride-induced neuronal apoptosis in cortex and hippocampus of mice brain |
| - | in-vivo, | AD, | NA | - | in-vivo, | Park, | NA |
| 2861- | FIS, | The neuroprotective effects of fisetin, a natural flavonoid in neurodegenerative diseases: Focus on the role of oxidative stress |
| - | Review, | Nor, | NA | - | Review, | Stroke, | NA | - | Review, | Park, | NA |
| 6923- | Flav, | Flavonoids: an overview |
| - | Review, | Nor, | NA |
| 4107- | FLS, | Ex, | Combined effects of aerobic exercise and 40-Hz light flicker exposure on early cognitive impairments in Alzheimer's disease of 3×Tg mice |
| - | in-vivo, | AD, | NA |
| 6929- | FLS, | AudGS, | Multisensory gamma stimulation promotes glymphatic clearance of amyloid |
| - | in-vivo, | AD, | NA |
| 6931- | FLS, | Gamma frequency sensory stimulation in mild probable Alzheimer's dementia patients: Results of feasibility and pilot studies |
| - | Trial, | AD, | NA |
| 7016- | Fuc, | Therapies from Fucoidan: New Developments |
| - | Review, | Var, | NA |
| 4018- | FulvicA, | Fe, | Inhibitory Impacts of Fulvic Acid-Coated Iron Oxide Nanoparticles on the Amyloid Fibril Aggregations |
| - | in-vivo, | AD, | NA |
| 7833- | GA, | Neuroprotective Potential of Mung Bean (Vigna radiata L.) Polyphenols in Alzheimer's Disease: A Review |
| - | Review, | AD, | NA |
| 7212- | GBE, | The Use of Ginkgo Biloba L. as a Neuroprotective Agent in the Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 3723- | GBE, | Can We Use Ginkgo biloba Extract to Treat Alzheimer’s Disease? Lessons from Preclinical and Clinical Studies |
| - | Review, | AD, | NA |
| 7278- | GGB, | Ginkgolide B: mechanisms of neurobiological effects, prospects for use in the therapy of Alzheimer's disease |
| - | Review, | AD, | NA |
| 7251- | Gink, | Ginkgetin: A Promising Multitarget Agent for Diverse Diseases |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1333 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid